Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Aigen Investment Management LP

Aigen Investment Management LP grew its position in Insmed Incorporated (NASDAQ:INSM) by 193.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,936 shares of the biopharmaceutical company’s stock after purchasing an additional 7,867 shares during the period. Aigen Investment Management LP’s holdings in Insmed were worth $824,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Jennison Associates LLC increased its holdings in shares of Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock valued at $53,424,000 after purchasing an additional 4,560 shares during the period. Capital CS Group LLC acquired a new stake in Insmed during the fourth quarter worth about $586,000. Orion Portfolio Solutions LLC grew its holdings in Insmed by 48.5% during the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after acquiring an additional 9,170 shares during the period. Ally Bridge Group NY LLC grew its holdings in Insmed by 16.9% during the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after acquiring an additional 21,833 shares during the period. Finally, TimesSquare Capital Management LLC acquired a new stake in Insmed during the third quarter worth about $35,322,000.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares of the company’s stock, valued at $25,996,328.94. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Martina M.D. Flammer sold 3,344 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the sale, the insider now directly owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. This trade represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 550,957 shares of company stock valued at $42,859,028 over the last quarter. 4.60% of the stock is owned by insiders.

Insmed Price Performance

NASDAQ:INSM opened at $77.55 on Thursday. The stock has a 50 day moving average price of $75.46 and a 200 day moving average price of $73.84. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market cap of $14.04 billion, a PE ratio of -13.87 and a beta of 1.11. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Equities research analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Friday, February 21st. JPMorgan Chase & Co. raised their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. Royal Bank of Canada assumed coverage on Insmed in a report on Tuesday, February 25th. They set an “outperform” rating and a $100.00 target price on the stock. Stifel Nicolaus dropped their target price on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Finally, Morgan Stanley increased their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $91.60.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.